To add a bio or update investment portfolio click update information.
Oshen Bio
Investment Portfolio
Healome Therapeutics
7 Jul 2026
Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
Healome Therapeutics is a University of Birmingham spinout developing an eye-drop matrix technology that extends the residence time of therapeutics on the ocular surface. The platform is designed for use in dry eye disease, ocular surface inflammation, corneal injury and rare diseases causing severe ocular surface damage.
Scarlet Therapeutics
11 May 2026
Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases
Scarlet Therapeutics develops engineered red blood cells designed to treat metabolic diseases and address shortages in rare blood supplies. Scarlet Therapeutics uses synthetic biology and proprietary cell line technology to create lab-grown red blood cells that can be manufactured at scale for therapeutic and transfusion use.
Oshen Bio
- 2(12 months)
- oshenbio.com
- Update Information
More venture news
- 4 Sept 2026
AI ScoreAI Score lands a £4m seed round led by Fuel Ventures to track and control AI usage within organisations
SeedAI - 2 Sept 2026
Ki 13Ki 13 unlocks a £3.7m seed round led by HICO Investment Group to make green hydrogen and CO₂ from biomass
SeedEnergy - 1 Sept 2026
OrchestraOrchestra lands a £2.4m seed round led by Differential Ventures for control plane that runs data pipelines and AI agents together
SeedDeveloper Tools
